Lloyd Mitchell Segal - Mar 28, 2024 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Signature
/s/ Steve Forte, Attorney-in-Fact
Stock symbol
RPTX
Transactions as of
Mar 28, 2024
Transactions value $
-$23,776
Form type
4
Date filed
4/1/2024, 09:31 PM
Previous filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Shares Sale -$12.2K -2.65K -2.35% $4.62 110K Mar 28, 2024 See footnote F1, F2, F3, F4
transaction RPTX Common Shares Sale -$11.5K -2.49K -2.26% $4.63 108K Apr 1, 2024 See footnote F1, F4, F5
holding RPTX Common Shares 103K Mar 28, 2024 Direct F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4).
F3 The change in the total shares prior to the transactions reported herein reflects a change in form of ownership from direct to indirect, which was exempt from reporting pursuant to Rule 16a-13.
F4 These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.65 inclusive.
F6 Includes 1,217 shares, 967 shares and 2,000 shares acquired on February 15, 2023, August 15, 2023 and February 15, 2024, respectively, under the Issuer's employee stock purchase plan.